A practical reference on peptidase: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Early lichenologists later reclassified the species in different genera. For instance, Erik Acharius (1803) referred to it as Parmelia parietina in his work Methodus, and Giuseppe De Notaris (1847) listed it as Physcia parietina. Johannes M. Norman (1852) treated it under Teloschistes (a related genus of orange-colored lichens), calling it Teloschistes parietinus. The modern genus Xanthoria was established by Theodor Fries. In 1860, he formally recombined the species as Xanthoria parietina. In his treatment, Fries recognized a distinct form, which he called Xanthoria aureola, distinguishing it from the more common form of X. parietina. He described aureola as a primary and fundamental form of the species, particularly prevalent in Arctic regions, differing from typical X. parietina in its color, rigid thallus, and preference for exposed habitats. Fries also cited Acharius, who considered aureola an intermediate between Xanthoria elegans (now Rusavskia elegans) and X. parietina. These distinctions may have contributed to later taxonomic interpretations that recognized Xanthoria aureola as a separate species. Xanthoria parietina is the type species of the genus Xanthoria. The designated lectotype for Xanthoria parietina is the illustration cited by Linnaeus from Dillenius (1742). Due to its reclassification across different genera, Xanthoria parietina has accumulated many synonyms in the literature. In addition to generic transfers, various infraspecific taxa (forms, varieties, or subspecies) have been described, particularly regarding morphological variants.
== Research == Roy's researches during his stint in the US was on protein folding and nuclear magnetic resonance studies of DNA and those researches identified the first hydropathy model which helped in predicting the exteriors and interiors of proteins by analyzing sequence information. He is also reported to have performed the complete assignment of a nucleic acid imino proton spectra using Nuclear Overhauser effect, regio-specific isotope labeling of sugars in nucleic acids and working along with Ad Bax and R. H. Griffey, developed an indirect 2D-NMR detection method, all reported to be for the first time. Later focusing his attention on bacteriophage lambda, he studied the gene expression of the bacterial virus using its operator-repressor system. Through his collaborative work with Sankar Adhya in 1998, he elucidated the role of differential contact in the transcription regulation mechanism and demonstrated the theory in many genetic regulatory circuits. His current work is focused on peptide therapeutics and he holds patents for some of his work. Roy has published his research work through a number of articles published in peer-reviewed journals and ResearchGate, an online repository of scientific papers, has listed 155 of them. He is the Co-author of "Chemical Biology of the Genome" published by Elsevier/AP. He is a joint editor of Subcellular Biochemistry, volume on Proteins: Structure, Function, and Engineering published by Plenum Press, New York, USA and Protein-Protein interaction Regulators published by Royal Society of Chemistry, UK.
== Criminal trial == After being delayed for more than a year due to the COVID-19 pandemic, Vaught's trial began on March 21, 2022. Prosecutors portrayed the use of the override function as evidence of recklessness. On the other hand, defense experts testified that overrides were daily events at many hospitals, and Vaught testified that Vanderbilt's 2017 upgrade of its computer systems had caused such delays that nurses were instructed to use overrides to get medication that they needed. A Tennessee Bureau of Investigation agent testified that the medical center had a "heavy burden of responsibility" for the deadly medication error, but that the Bureau of Investigation only pursued criminal charges and penalties against the nurse, not the hospital. After Murphey's death, the hospital did not report the error to federal or state regulators (as required by law) and reported to the county medical examiner that Murphey died of natural causes with no mention of the vecuronium. The hospital also negotiated an out-of-court settlement with Murphey's family which prevents them from disclosing details of her death. On March 25, 2022, the jury convicted Vaught of gross neglect of an impaired adult and negligent homicide, which carries a maximum sentence of eight years in prison. She was acquitted of the more serious charge of reckless homicide. On May 13, 2022, Judge Jennifer Smith ruled that Vaught would not have to spend time in prison, sentencing her instead to three years' probation.
Tea is the most consumed manufactured drink in the world, equalling all others combined, including coffee, soft drinks, and alcohol. Most tea consumed outside East Asia is produced on large plantations in the hilly regions of India and Sri Lanka and is destined to be sold to large businesses. Opposite this large-scale industrial production are many small "gardens," sometimes minuscule plantations, that produce highly sought-after teas prized by gourmets. India is the world's largest tea-drinking nation, although the per capita consumption of tea remains a modest 750 grams (26 oz) per person every year. Turkey, with 2.5 kilograms (5 lb 8 oz) of tea consumed per person per year, is the world's greatest per capita consumer.
Sources: en.wikipedia.org
== Structural studies == As of late 2007, 15 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1S5B, PDB: 1S5C, PDB: 1S5D, PDB: 1S5E, PDB: 1S5F, PDB: 1SGK, PDB: 1TOX, PDB: 1XDT, PDB: 1XK9, PDB: 1ZM3, PDB: 1ZM4, PDB: 1ZM9, PDB: 2A5D, PDB: 2A5F, and PDB: 2A5G.
The vagina is attached to the pelvic walls by endopelvic fascia. The peritoneum is the external layer of skin that covers the fascia. This tissue provides additional support to the pelvic floor. The endopelvic fascia is one continuous sheet of tissue and varies in thickness. It permits some shifting of the pelvic structures. The fascia contains elastic collagen fibers in a 'mesh-like' structure. The fascia also contains fibroblasts, smooth muscle, and vascular vessels. The cardinal ligament supports the apex of the vagina and derives some of its strength from vascular tissue. The endopelvic fascia attaches to the lateral pelvic wall via the arcus tendineus.
Whereas MDA and psychedelics like psilocybin induce the head-twitch response in rodents, a behavioral proxy of psychedelic effects, findings on MDMA and the head-twitch response are mixed and conflicting. In addition, whereas MDA fully substitutes for psychedelics like LSD and DOM in rodent drug discrimination tests, MDMA does not do so, nor do psychedelics generally fully substitute for MDMA. Long-term repeated activation of serotonin 5-HT2B receptors by MDMA is thought to result in increased risk of organ complications such as valvular heart disease (VHD) and primary pulmonary hypertension (PPH). MDMA has been associated with serotonergic neurotoxicity. This may be due to formation of toxic MDMA metabolites and/or induction of simultaneous serotonin and dopamine release, with consequent uptake of dopamine into serotonergic neurons and breakdown into toxic species. Serotonin 5-HT2 receptor agonists or serotonergic psychedelics may potentiate the neurotoxicity of MDMA. MDMA is a racemic mixture of two enantiomers, (S)-MDMA and (R)-MDMA. (S)-MDMA is much more potent as an SNDRA in vitro and in producing MDMA-like subjective effects in humans than (R)-MDMA. By contrast, (R)-MDMA acts as a lower-potency serotonin–norepinephrine releasing agent (SNRA) with weak or negligible effects on dopamine. Relatedly, (R)-MDMA shows weak or negligible stimulant-like and rewarding effects in animals. Both (S)-MDMA and (R)-MDMA produce entactogen-type effects in animals and humans. In addition, both (S)-MDMA and (R)-MDMA are weak agonists of the serotonin 5-HT2 receptors.
In 2005–2006, it was the 15th-most-prevalent allergen in patch tests (3.4%) of people with suspected allergic contact dermatitis. It is used as a substitute for formaldehyde, a disinfectant and preservative, in solvents. It is prevalent in skin and personal care products and topical medications.
==== Reduced probability of contamination ==== DMF-based workflows, particularly those using a closed configuration with a top-plate ground electrode, have been shown to be less susceptible to outside contamination compared to some conventional laboratory workflows. This can be attributed to minimal user interaction during automated steps, and the fact that the smaller volumes are less exposed to environmental contaminants than larger volumes which would need to be exposed to open air during mixing. Ruan et al. observed minimal contamination from exogenous nonhuman DNA and no cross-contamination between samples while using their DMF-based digital whole genome sequencing system.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.